Search

Your search keyword '"De Cobelli, F"' showing total 1,253 results
Start Over Author "De Cobelli, F"
1,253 results on '"De Cobelli, F"'

1. Early regression index (ERI) on MR images as response predictor in esophageal cancer treated with neoadjuvant chemo-radiotherapy: Interim analysis of the prospective ESCAPE trial

Author

Fiorino, C., Palumbo, D., Mori, M., Palazzo, G., Pellegrini, A.E., Albarello, L., Belardo, A., Canevari, C., Cossu, A., Damascelli, A., Elmore, U., Mazza, E., Pavarini, M., Passoni, P., Puccetti, F., Slim, N., Steidler, S., Del Vecchio, A., Di Muzio, N.G., Chiti, A., Rosati, R., and De Cobelli, F.

Published
2024
Full Text
View/download PDF

3. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author

Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Å., Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.

Published
2022
Full Text
View/download PDF

4. 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours

Author

Mapelli, P., Bezzi, C., Palumbo, D., Canevari, C., Ghezzo, S., Samanes Gajate, A. M., Catalfamo, B., Messina, A., Presotto, L., Guarnaccia, A., Bettinardi, V., Muffatti, F., Andreasi, V., Schiavo Lena, M., Gianolli, L., Partelli, S., Falconi, M., Scifo, P., De Cobelli, F., and Picchio, M.

Published
2022
Full Text
View/download PDF

5. Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis

Author

Rimini, M., Rimassa, L., Ueshima, K., Burgio, V., Shigeo, S., Tada, T., Suda, G., Yoo, C., Cheon, J., Pinato, D.J., Lonardi, S., Scartozzi, M., Iavarone, M., Di Costanzo, G.G., Marra, F., Soldà, C., Tamburini, E., Piscaglia, F., Masi, G., Cabibbo, G., Foschi, F.G., Silletta, M., Pressiani, T., Nishida, N., Iwamoto, H., Sakamoto, N., Ryoo, B.-Y., Chon, H.J., Claudia, F., Niizeki, T., Sho, T., Kang, B., D’Alessio, A., Kumada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Fukunishi, S., Tsuji, K., Ishikawa, T., Tajiri, K., Ochi, H., Yasuda, S., Toyoda, H., Ogawa, C., Nishimur, T., Hatanaka, T., Kakizaki, S., Shimada, N., Kawata, K., Tanaka, T., Ohama, H., Nouso, K., Morishita, A., Tsutsui, A., Nagano, T., Itokawa, N., Okubo, T., Arai, T., Imai, M., Naganuma, A., Koizumi, Y., Nakamura, S., Joko, K., Iijima, H., Hiasa, Y., Pedica, F., De Cobelli, F., Ratti, F., Aldrighetti, L., Kudo, M., Cascinu, S., and Casadei-Gardini, A.

Published
2022
Full Text
View/download PDF

6. Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy

Author

Burgio V, Iavarone M, Di Costanzo GG, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Celsa C, Foschi FG, Silletta M, Amoruso DC, Rimini M, Bruccoleri M, Tortora R, Campani C, Soldà C, Viola MG, Forgione A, Conti F, Salani F, Catanese S, Giacchetto CM, Fulgenzi C, Coppola C, Lampertico P, Pellino A, Rancatore G, Cabibbo G, Ratti F, Pedica F, Della Corte A, Colombo M, De Cobelli F, Aldrighetti L, Cascinu S, and Casadei-Gardini A

Subjects
hepatocarcinoma, sorafenib, lenvatinib, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Valentina Burgio,1 Massimo Iavarone,2 Giovanni Giuseppe Di Costanzo,3 Fabio Marra,4 Sara Lonardi,5,6 Emiliano Tamburini,7 Fabio Piscaglia,8 Gianluca Masi,9,10 Ciro Celsa,11 Francesco Giuseppe Foschi,12 Marianna Silletta,13 Daniela Caterina Amoruso,14 Margherita Rimini,15 Mariangela Bruccoleri,2 Raffaella Tortora,3 Claudia Campani,4 Caterina Soldà,6 Massimo Giuseppe Viola,16 Antonella Forgione,8 Fabio Conti,12 Francesca Salani,9,10 Silvia Catanese,9,10 Carmelo Marco Giacchetto,17 Claudia Fulgenzi,13 Carmine Coppola,14 Pietro Lampertico,18 Antonio Pellino,6,19 Gabriele Rancatore,17 Giuseppe Cabibbo,17 Francesca Ratti,20 Federica Pedica,21 Angelo Della Corte,22 Massimo Colombo,18 Francesco De Cobelli,23 Luca Aldrighetti,20 Stefano Cascinu,1,23 Andrea Casadei-Gardini1,23 1Department of Medical Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 2Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Division of Gastroenterology and Hepatology, Milan, Italy; 3Department of Hepatology, Naples, 80131, Italy; 4Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Firenze, Italy; 5Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy; 6Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 7Department of Oncology and Palliative Care, Cardinale Hospital, Naples, Italy; 8Division of Internal Medicine, Hepatobiliary and Immunoallergic Disease, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; 9Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy; 10Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; 11Department of Surgical, Oncological and Oral Sciences (Di.Chir.On.S.), University of Palermo, Palermo, 90127, Italy; 12Internal Medicine, Infermi Hospital, Faenza (AUSL ROMAGNA), Ravenna, Italy; 13Department of Oncology, Campus Bio Medico, Roma, Italy; 14Hepatology Unit, Internal Medicine, Area Stabiese Hospital, Naples, Italy; 15Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, Modena, 4121, Italy; 16Department of General Surgery and Emergency Surgery, Cardinale Hospital, Tricase, Italy; 17Section of Gastroenterology & Hepatology, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, PROMISE, University of Palermo, Palermo, 90127, Italy; 18Liver Center, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 19Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; 20Hepatobiliary Surgery Division, Liver Center, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 21Department of Experimental Oncology, Pathology Unit, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 22Department of Radiology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute, Milan, 20132, Italy; 23School of Medicine, Vita-Salute San Raffaele University, Milan, 20132, ItalyCorrespondence: Andrea Casadei-GardiniDepartment of Medical Oncology, IRCCS San Raffaele Hospital, Via Olgettina n. 60, Milan, ItalyEmail casadeigardini@gmail.comBackground: Lenvatinib has been approved in Italy since October 2019 as a first-line therapy for advanced hepatocellular carcinoma (HCC) and to date data on effectiveness and safety of lenvatinib are not available in our region. To fill this gap, we performed a multicentric analysis of the real-world treatment outcomes with the propensity score matching in a cohort of Italian patients with unresectable HCC who were treated with either sorafenib or lenvatinib.Aims and Methods: To evaluate the effectiveness of sorafenib and lenvatinib as primary treatment of advanced HCC in clinical practice we performed a multicentric analysis of the treatment outcomes of 288 such patients recruited in 11 centers in Italy. A propensity score was used to mitigate confounding due to referral biases in the assessment of mortality and progression-free survival.Results: Over a follow-up period of 11 months the Cox regression model showed 48% reduction of death risk for patients treated with lenvatinib (95% CI: 0.34– 0.81; p = 0.0034), compared with those treated with sorafenib. The median PFS was 9.0 and 4.9 months for lenvatinib and sorafenib arm, respectively. Patients treated with lenvatinib showed a higher percentage of response rate (29.4% vs 2.8%; p < 0.00001) compared with patients treated with sorafenib. Sorafenib was shown to be correlated with more HFSR, diarrhea and fatigue, while lenvatinib with more hypertension and fatigue.Conclusion: Our study highlighted for the first time the efficacy and safety of lenvatinib in an Italian cohort of patients.Keywords: hepatocarcinoma, sorafenib, lenvatinib

Published
2021

9. Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series

Author

Quarta, L., primary, Stabile, A., additional, Barletta, F., additional, Mazzone, E., additional, Cannoletta, D., additional, Pellegrino, F., additional, Sorce, G., additional, Pellegrino, A., additional, Cucchiara, V., additional, Scuderi, S., additional, Robesti, D., additional, Leni, R., additional, Bianchi, M., additional, Longoni, M., additional, Scilipoti, P., additional, De Cobelli, F., additional, Esposito, A., additional, Gandaglia, G., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

10. How to perform the optimal renal biopsy: A machine learning-based indication

Author

Belladelli, F., primary, Re, C., additional, Cei, F., additional, Musso, G., additional, Rosiello, G., additional, Cignoli, D., additional, Canibus, D., additional, Fiorio, F., additional, Bertini, R., additional, Salonia, A., additional, De Cobelli, F., additional, Brembilla, G., additional, Esposito, A., additional, Palmisano, A., additional, Piccolo, C., additional, Gambirasio, M., additional, Lucianò, R., additional, Tenace, N., additional, Briganti, A., additional, Montorsi, F., additional, Larcher, A., additional, and Capitanio, U., additional

Published
2024
Full Text
View/download PDF

12. Assessing epigenetic features associated with lymph node metastases in prostate cancer

Author

Bandini, M., primary, Zaurito, P., additional, Barletta, F., additional, Cirulli, G.O., additional, Lucianò, R., additional, Giannese, F., additional, Scotti, G.M., additional, Cucchiara, V., additional, Stabile, A., additional, Mazzone, E., additional, Oneto, C., additional, Sorce, G., additional, Tenace, N.P., additional, Scarfò, F., additional, Brembilla, G., additional, Esposito, A., additional, Morelli, M., additional, Lazarevic, D., additional, De Cobelli, F., additional, Doglioni, C., additional, Tonon, G., additional, Gandaglia, G., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

13. PSMA radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Updated results of a planned interim analysis of a prospective phase 2 study

Author

Quarta, L., primary, Mazzone, E., additional, Gandaglia, G., additional, Stabile, A., additional, Pellegrino, A., additional, Cucchiara, V., additional, Barletta, F., additional, Scuderi, S., additional, Robesti, D., additional, Leni, R., additional, Cannoletta, D., additional, Zaurito, P., additional, Samanes Gajate, A.M., additional, Picchio, M., additional, Chiti, A., additional, Brembilla, G., additional, De Cobelli, F., additional, Van Oosterom, M.N., additional, Van Leeuwen, F.W.B., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

14. A novel PRECISE implemented predictive model to assess the risk of long-term disease reclassification in men on active surveillance. Results from a large, single institution series

Author

Stabile, A., primary, Leni, R., additional, Quarta, L., additional, Mazzone, E., additional, Cannoletta, D., additional, Gandaglia, G., additional, Pellegrino, F., additional, Sorce, G., additional, Pellegrino, A., additional, Russo, T., additional, Cosenza, M., additional, Pennella, R., additional, Brembilla, G., additional, De Cobelli, F., additional, Cucchiara, V., additional, Scuderi, S., additional, Robesti, D., additional, Karnes, R.J., additional, Roupret, M., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

15. First results of NURE-Combo: A phase 2 study of neoadjuvant Nivolumab (NIVO) and Nab-Paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with Muscle-Invasive Bladder Cancer (MIBC)

Author

Mercinelli, C., primary, Basile, G., additional, Raggi, D., additional, Cigliola, A., additional, Tateo, V., additional, Patanè, D.A., additional, Crupi, E., additional, Costa De Padua, T., additional, Colecchia, M., additional, Colombo, R., additional, Moschini, M., additional, Re, C., additional, Avesani, G., additional, Brembilla, G., additional, De Cobelli, F., additional, Briganti, A., additional, Pavlick, D.C., additional, Ross, J.S., additional, Montorsi, F., additional, and Necchi, A., additional

Published
2024
Full Text
View/download PDF

16. The role of artificial intelligence for the detection of clinically significant prostate cancer at multiparametric magnetic resonance imaging

Author

Quarta, L., primary, Scuderi, S., additional, Gandaglia, G., additional, Stabile, A., additional, Marzorati, C., additional, Russo, T., additional, Brembilla, G., additional, Camisassa, E., additional, Leni, R., additional, Cucchiara, V., additional, Bianchi, M., additional, Cannoletta, D., additional, Zaurito, P., additional, Barletta, F., additional, Cosenza, M., additional, Robesti, D., additional, Mazzone, E., additional, De Cobelli, F., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

17. Optimizing the number of systematic cores during MRI target biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial

Author

Cannoletta, D., primary, Stabile, A., additional, Barletta, F.M., additional, Quarta, L., additional, Mazzone, E., additional, Gandaglia, G., additional, Cucchiara, V., additional, Scuderi, S., additional, Robesti, D., additional, Leni, R., additional, Cirulli, G.O., additional, Sorce, G., additional, Pellegrino, F., additional, Bianchi, M., additional, De Cobelli, F., additional, Brembilla, G., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

18. Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

Author

Quarta, L., primary, Stabile, A., additional, Barletta, F., additional, Mazzone, E., additional, Cannoletta, D., additional, Pellegrino, F., additional, Sorce, G., additional, Pellegrino, A., additional, Cucchiara, V., additional, Scuderi, S., additional, Robesti, D., additional, Leni, R., additional, Gandaglia, G., additional, Bianchi, M., additional, De Cobelli, F., additional, Brembilla, G., additional, Roupret, M., additional, Karnes, R.J., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

19. How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series

Author

Pellegrino, A., primary, Stabile, A., additional, Quarta, L., additional, Barletta, F., additional, Mazzone, E., additional, Cannoletta, D., additional, Pellegrino, F., additional, Sorce, G., additional, Cucchiara, V., additional, Scuderi, S., additional, Robesti, D., additional, Leni, R., additional, Cirulli, G.O., additional, Longoni, M., additional, Scilipoti, P., additional, De Angelis, M., additional, De Cobelli, F., additional, Esposito, A., additional, Gandaglia, G., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2024
Full Text
View/download PDF

22. Perioperative and long-term oncological outcomes after local tumor ablation for complex (PADUA Score =10) cT1a renal tumors: a multicenter analysis

Author

Piazza, P., primary, Bianchi, L., additional, Luzzago, S., additional, Bandini, M., additional, Mottaran, A., additional, Amirhassankhani, S., additional, De Concilio, B., additional, Celia, A., additional, Serra, C., additional, Cappelli, A., additional, Golfieri, R., additional, Musi, G., additional, Gallina, A., additional, Rizzo, M., additional, Liguori, G., additional, Trombetta, C., additional, De Cobelli, F., additional, Mauri, G., additional, Orsi, F., additional, Capitanio, U., additional, Schiavina, R., additional, De Cobelli, O., additional, Montorsi, F., additional, and Brunocilla, E., additional

Published
2023
Full Text
View/download PDF

25. Proposal and internal validation of a nomogram for the prediction of local recurrence-free survival after percutaneous ablation for ct1 renal masses

Author

Mottaran, A., primary, Nocera, L., additional, Bianchi, L., additional, Luzzago, S., additional, Bandini, M., additional, Piazza, P., additional, Celia, A., additional, Serra, C., additional, Cappelli, A., additional, De Cinque, A., additional, Modestino, F., additional, Golfieri, R., additional, Musi, G., additional, Gallina, A., additional, De Cobelli, F., additional, Mauri, G., additional, Orsi, F., additional, Capitanio, U., additional, Schiavina, R., additional, De Cobelli, O., additional, Montorsi, F., additional, and Brunocilla, E., additional

Published
2023
Full Text
View/download PDF

26. Renal tumor heterogeneity in sporadic and inherited renal cancer: a translational multimodal approach

Author

Capitanio, U., primary, Larcher, A., additional, Rowe, I., additional, Belladelli, F., additional, Cei, F., additional, Re, C., additional, Lucianò, R., additional, Colciago, G., additional, Corea, F., additional, Palmisano, A., additional, Esposito, A., additional, De Cobelli, F., additional, Tonon, G., additional, Pandolfo, S.D., additional, Verze, P., additional, Pipitone, G.B., additional, Carrera, P., additional, Scotti, G.M., additional, Bertini, R., additional, Bernardi, R., additional, Montorsi, F., additional, and Salonia, A., additional

Published
2023
Full Text
View/download PDF

27. BOOTSTRAP-BASED MACHINE LEARNING TO ROBUSTLY CHARACTERIZE PANCREATIC NEUROENDOCRINE NEOPLASMS (PANNEN) BASED ON CT RADIOMIC FEATURES

Author

Mori, M., primary, Palumbo, D., additional, Muffatti, F., additional, Partelli, S., additional, Mushtaq, J., additional, Andreasi, V., additional, Prato, F., additional, Ubeira-Gabellini, M.G., additional, Palazzo, G., additional, Falconi, M., additional, Del Vecchio, A., additional, De Cobelli, F., additional, and Fiorino, C., additional

Published
2023
Full Text
View/download PDF

31. Embolisation of the parenchymal tract after percutaneous portal vein catheterization: a retrospective comparison of outcomes with different techniques in two centres

Author

Marra, P, Carbone, F, Augello, L, Dulcetta, L, Muglia, R, Bonaffini, P, Della Corte, A, Steidler, S, Gusmini, S, Guazzarotti, G, Palumbo, D, Venturini, M, De Cobelli, F, Sironi, S, Marra P., Carbone F. S., Augello L., Dulcetta L., Muglia R., Bonaffini P. A., Della Corte A., Steidler S., Gusmini S., Guazzarotti G., Palumbo D., Venturini M., De Cobelli F., Sironi S., Marra, P, Carbone, F, Augello, L, Dulcetta, L, Muglia, R, Bonaffini, P, Della Corte, A, Steidler, S, Gusmini, S, Guazzarotti, G, Palumbo, D, Venturini, M, De Cobelli, F, Sironi, S, Marra P., Carbone F. S., Augello L., Dulcetta L., Muglia R., Bonaffini P. A., Della Corte A., Steidler S., Gusmini S., Guazzarotti G., Palumbo D., Venturini M., De Cobelli F., and Sironi S.

Abstract

Background: Embolisation of the parenchymal tract is a key step after any other transhepatic or transplenic percutaneous portal vein catheterization since eventual venous bleeding is difficult to control and may require surgical management. Different techniques have been proposed to perform tract embolisation. The aim of this study is to compare the safety and efficacy of different techniques of haemostasis of the parenchymal tract. Materials and methods: All the interventional procedures with percutaneous transhepatic or transplenic access to the portal vein (excluding ipsilateral portal vein embolisation) from January 2010 to July 2020, in two tertiary hospitals, were retrospectively analyzed. The following data were evaluated: access site, the technique of embolisation, technical success in terms of immediate thrombosis of the tract, safety and clinical efficacy in terms of the absence of hemorrhagic and thrombotic complications. Results: One-hundred-sixty-one patients underwent 220 percutaneous transhepatic or transplenic portal vein catheterization procedures. The main indications were pancreatic islet transplantation, portal anastomotic stenosis after liver transplantation, and portal vein thrombosis recanalization. As embolic materials gelfoam was used in 105 cases, metallic micro-coils in 54 cases, and cyanoacrylic glue in 44 cases; in 17 cases the parenchymal tract was not embolized. Technical success was 98% without significant difference among groups (p-value = 0.22). Eighteen post-procedural abdominal bleedings occurred, all grade 3 and were managed conservatively; difference among groups was not significant (p-value = 0.25). We detected 12 intrahepatic portal branch thromboses not related to the embolisation technique; only one case of non-target embolisation was documented after liver tract embolisation with glue, without clinical consequences. Conclusion: Embolisation of the parenchymal tract after percutaneous portal vein catheterization is technical

Published
2022

32. Radiomics and artificial intelligence

Author

Catalano, OA, Ghezzo, S, Bezzi, C, Neri, I, Mapelli, P, Presotto, L, Gajate, A, Bettinardi, V, Garibotto, V, De Cobelli, F, Scifo, P, Picchio, M, Ghezzo S., Bezzi C., Neri I., Mapelli P., Presotto L., Gajate A. M. S., Bettinardi V., Garibotto V., De Cobelli F., Scifo P., Picchio M., Catalano, OA, Ghezzo, S, Bezzi, C, Neri, I, Mapelli, P, Presotto, L, Gajate, A, Bettinardi, V, Garibotto, V, De Cobelli, F, Scifo, P, Picchio, M, Ghezzo S., Bezzi C., Neri I., Mapelli P., Presotto L., Gajate A. M. S., Bettinardi V., Garibotto V., De Cobelli F., Scifo P., and Picchio M.

Abstract

Positron emission tomography/magnetic resonance imaging (PET/MRI) is an innovative imaging technology that allows the simultaneous acquisition of metabolic, structural, and functional information for an accurate characterization of tissues. The qualitative interpretation of PET/MR images has shown great potential in tumor diagnosis, treatment planning, and follow-up. Furthermore, PET/MRI also potentially provides several quantitative imaging biomarkers, also called “radiomic features,” for tumor characterization extracted both from PET and MRI. In the new era of precision medicine, radiomics is an emerging translational field of research aiming to extract a large number of quantitative features followed by their interpretation through various analyses and integration into predictive models. In this chapter, different clinical applications of radiomics based on PET, MRI, and PET/MR images will be presented, with a specific focus on the characterization of brain tumors, breast cancer, pancreatic neuroendocrine tumors, and prostate cancer. Finally, some other applications of artificial intelligence applied to PET/MR images that can shortly enter into clinical practice will be shown.

Published
2022

33. State of the art of radiomic analysis in the clinical management of prostate cancer: A systematic review

Author

Ghezzo, S, Bezzi, C, Presotto, L, Mapelli, P, Bettinardi, V, Savi, A, Neri, I, Preza, E, Samanes Gajate, A, De Cobelli, F, Scifo, P, Picchio, M, Ghezzo S., Bezzi C., Presotto L., Mapelli P., Bettinardi V., Savi A., Neri I., Preza E., Samanes Gajate A. M., De Cobelli F., Scifo P., Picchio M., Ghezzo, S, Bezzi, C, Presotto, L, Mapelli, P, Bettinardi, V, Savi, A, Neri, I, Preza, E, Samanes Gajate, A, De Cobelli, F, Scifo, P, Picchio, M, Ghezzo S., Bezzi C., Presotto L., Mapelli P., Bettinardi V., Savi A., Neri I., Preza E., Samanes Gajate A. M., De Cobelli F., Scifo P., and Picchio M.

Abstract

We present the current clinical applications of radiomics in the context of prostate cancer (PCa) management. Several online databases for original articles using a combination of the following keywords: “(radiomic or radiomics) AND (prostate cancer or prostate tumour or prostate tumor or prostate neoplasia)” have been searched. The selected papers have been pooled as focus on (i) PCa detection, (ii) assessing the clinical significance of PCa, (iii) biochemical recurrence prediction, (iv) radiation-therapy outcome prediction and treatment efficacy monitoring, (v) metastases detection, (vi) metastases prediction, (vii) prediction of extra-prostatic extension. Seventy-six studies were included for qualitative analyses. Classifiers powered with radiomic features were able to discriminate between healthy tissue and PCa and between low- and high-risk PCa. However, before radiomics can be proposed for clinical use its methods have to be standardized, and these first encouraging results need to be robustly replicated in large and independent cohorts.

Published
2022

34. 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine well-differentiated tumours

Author

Mapelli, P, Bezzi, C, Palumbo, D, Canevari, C, Ghezzo, S, Samanes Gajate, A, Catalfamo, B, Messina, A, Presotto, L, Guarnaccia, A, Bettinardi, V, Muffatti, F, Andreasi, V, Schiavo Lena, M, Gianolli, L, Partelli, S, Falconi, M, Scifo, P, De Cobelli, F, Picchio, M, Mapelli P., Bezzi C., Palumbo D., Canevari C., Ghezzo S., Samanes Gajate A. M., Catalfamo B., Messina A., Presotto L., Guarnaccia A., Bettinardi V., Muffatti F., Andreasi V., Schiavo Lena M., Gianolli L., Partelli S., Falconi M., Scifo P., De Cobelli F., Picchio M., Mapelli, P, Bezzi, C, Palumbo, D, Canevari, C, Ghezzo, S, Samanes Gajate, A, Catalfamo, B, Messina, A, Presotto, L, Guarnaccia, A, Bettinardi, V, Muffatti, F, Andreasi, V, Schiavo Lena, M, Gianolli, L, Partelli, S, Falconi, M, Scifo, P, De Cobelli, F, Picchio, M, Mapelli P., Bezzi C., Palumbo D., Canevari C., Ghezzo S., Samanes Gajate A. M., Catalfamo B., Messina A., Presotto L., Guarnaccia A., Bettinardi V., Muffatti F., Andreasi V., Schiavo Lena M., Gianolli L., Partelli S., Falconi M., Scifo P., De Cobelli F., and Picchio M.

Abstract

Purpose: To explore the role of fully hybrid 68Ga-DOTATOC PET/MR imaging and radiomic parameters in predicting histopathological prognostic factors in patients with pancreatic neuroendocrine tumours (PanNETs) undergoing surgery. Methods: One hundred eighty-seven consecutive 68Ga-DOTATOC PET/MRI scans (March 2018–June 2020) performed for gastroenteropancreatic neuroendocrine tumour were retrospectively evaluated; 16/187 patients met the eligibility criteria (68Ga-DOTATOC PET/MRI for preoperative staging of PanNET and availability of histological data). PET/MR scans were qualitatively and quantitatively interpreted, and the following imaging parameters were derived: PET-derived SUVmax, SUVmean, somatostatin receptor density (SRD), total lesion somatostatin receptor density (TLSRD), and MRI-derived apparent diffusion coefficient (ADC), arterial and late enhancement, necrosis, cystic degeneration, and maximum diameter. Additionally, first-, second-, and higher-order radiomic parameters were extracted from both PET and MRI scans. Correlations with several PanNETs’ histopathological prognostic factors were evaluated using Spearman’s coefficient, while the area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to evaluate parameters’ predictive performance. Results: Primary tumour was detected in all 16 patients (15/16 by 68Ga-DOTATOC PET and 16/16 by MRI). SUVmax and SUVmean resulted good predictors of lymphnodal (LN) involvement (AUC of 0.850 and 0.783, respectively). Second-order radiomic parameters GrayLevelVariance and HighGrayLevelZoneEmphasis extracted from T2 MRI demonstrated significant correlations with LN involvement (adjusted p = 0.009), also showing good predictive performance (AUC = 0.992). Conclusion: This study demonstrates the role of the fully hybrid PET/MRI tool for the synergic function of imaging parameters extracted by the two modalities and highlights the potentiality of imaging and radiomic parameters in assessing h

Published
2022

35. PO-1355 Impact of lymphopenia in patients with esophageal cancer after neoadjuvant chemoradiotherapy

Author

SLIM, N., primary, Chissotti, C., additional, Passoni, P., additional, Tummineri, R., additional, Zerbetto, F., additional, Torrisi, M., additional, Giannini, L., additional, Midulla, M., additional, Ferrario, F., additional, Villa, S., additional, Mazza, E., additional, Albarello, L., additional, De Cobelli, F., additional, Rosati, R., additional, Cascinu, S., additional, and Di Muzio, N.G., additional

Published
2023
Full Text
View/download PDF

36. The impact of a multidisciplinary team evaluation on the diagnosis and management of acute and chronic pancreatitis in a tertiary referral center

Author

Lauri, G., additional, Tacelli, M., additional, Belfiori, G., additional, Palumbo, D., additional, Aleotti, F., additional, Lanzillotta, M., additional, Ponz de Leon Pisani, R., additional, Bina, N., additional, Dell'Anna, G., additional, Zaccari, P., additional, Vanella, G., additional, Archibugi, L., additional, Balzano, G., additional, Petrone, M. C., additional, Rossi, G., additional, Tamburrino, D., additional, Mariani, A., additional, Doglioni, C., additional, Della Torre, E., additional, De Cobelli, F., additional, Falconi, M., additional, Arcidiacono, P. G., additional, Crippa, S., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

37. OC.09.4 THE IMPACT OF A MULTIDISCIPLINARY TEAM EVALUATION ON THE DIAGNOSIS AND MANAGEMENT OF ACUTE AND CHRONIC PANCREATITIS IN A TERTIARY REFERRAL CENTER

Author

Lauri, G., primary, Tacelli, M., additional, Palumbo, D., additional, Aleotti, F., additional, Lanzillotta, M., additional, Ponz De Leon Pisani, R., additional, Bina, N., additional, Dell'Anna, G., additional, Zaccari, P., additional, Vanella, G., additional, Archibugi, L., additional, Balzano, G., additional, Petrone, M.C., additional, Rossi, G., additional, Tamburrino, D., additional, Mariani, A., additional, Doglioni, C., additional, Della Torre, E., additional, De Cobelli, F., additional, Falconi, M., additional, Arcidiacono, P., additional, Crippa, S., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

43. Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group

Author

Mauri G., Bernardi S., Palermo A., Cesareo R., Papini E., Solbiati L., Barbaro D., Monti S., Deandrea M., Fugazzola L., Gambelunghe G., Negro R., Spiezia S., Stacul F., Sconfienza L. M., Cavallaro M., Achille G., Cantisani V., Cozzaglio L., Crescenzi A., De Cobelli F., Garberoglio R., Giugliano G., Persani L., Raggiunti B., Seregni E., Van Doorne D., Frasoldati A., Carzaniga C., Lombardi C. P., Papi G., Guglielmi R., Orsi F., Cervelli R., Barbieri C., Trimboli P., Monzani D., Mauri G., Bernardi S., Palermo A., Cesareo R., Papini E., Solbiati L., Barbaro D., Monti S., Deandrea M., Fugazzola L., Gambelunghe G., Negro R., Spiezia S., Stacul F., Sconfienza L.M., Cavallaro M., Achille G., Cantisani V., Cozzaglio L., Crescenzi A., De Cobelli F., Garberoglio R., Giugliano G., Persani L., Raggiunti B., Seregni E., Van Doorne D., Frasoldati A., Carzaniga C., Lombardi C.P., Papi G., Guglielmi R., Orsi F., Cervelli R., Barbieri C., Trimboli P., Monzani D., Mauri, G., Bernardi, S., Palermo, A., Cesareo, R., Papini, E., Solbiati, L., Barbaro, D., Monti, S., Deandrea, M., Fugazzola, L., Gambelunghe, G., Negro, R., Spiezia, S., Stacul, F., Sconfienza, L. M., Cavallaro, M., Achille, G., Cantisani, V., Cozzaglio, L., Crescenzi, A., De Cobelli, F., Garberoglio, R., Giugliano, G., Persani, L., Raggiunti, B., Seregni, E., Van Doorne, D., Frasoldati, A., Carzaniga, C., Lombardi, C. P., Papi, G., Guglielmi, R., Orsi, F., Cervelli, R., Barbieri, C., Trimboli, P., and Monzani, D.

Subjects
Patient, Ethanol, Endocrinology, Diabetes and Metabolism, Laser, Thyroid Function Tests, Thyroid Function Test, Endocrinology, Treatment Outcome, Physician, Radiofrequency, Physicians, Practice Guidelines as Topic, Catheter Ablation, Humans, Microwave, Thyroid nodule, Thyroid Nodule, Human
Abstract

Purpose In this paper, the members of the Italian Working Group on Minimally-Invasive Treatments of the Thyroid (MITT group) aim to summarize the most relevant information that could be of help to referring physicians and that should be provided to patients when considering the use of MITT for the treatment of benign thyroid nodules. Methods An interdisciplinary board of physicians with specific expertise in the management of thyroid nodules was appointed by the Italian MITT Group. A systematic literature search was performed, and an evidence-based approach was used, including also the knowledge and the practical experience of the panelists to develop the paper. Results The paper provides a list of questions that are frequently asked by patients to operators performing MITT, each with a brief and detailed answer and more relevant literature references to be consulted. Conclusions This paper summarizes the most relevant information to be provided to patients and general practitioners/referring physicians about the use of MITT for the treatment of benign thyroid nodules.

Published
2022

44. Concordance of renal sinus or calyces invasion between preoperative imaging and final pathology after surgery for kidney cancer

Author

Cei, F., primary, Tenace, N., additional, Basile, G., additional, Musso, G., additional, Re, C., additional, Fallara, G., additional, Rosiello, G., additional, Belladelli, F., additional, Cignoli, D., additional, Canibus, D., additional, Rowe, I., additional, De Cobelli, F., additional, Brembilla, G., additional, Pennella, R., additional, Della Corte, A., additional, Guazzarotti, G., additional, Bertini, R., additional, Briganti, A., additional, Colecchia, M., additional, Montorsi, F., additional, Salonia, A., additional, Larcher, A., additional, Lucianò, R., additional, and Capitanio, U., additional

Published
2023
Full Text
View/download PDF

45. Oncologic outcomes of patients with incidental prostate cancer: Can we rely on multiparametric mri to exclude aggressive prostate cancer?

Author

Leni, R., primary, Robesti, D., additional, Lucianò, R., additional, Gandaglia, G., additional, Stabile, A., additional, Mazzone, E., additional, Cucchiara, V., additional, Quarta, L., additional, Zaurito, P., additional, Tenace, N.P., additional, De Angelis, M., additional, Pellegrino, A., additional, Zaffuto, E., additional, Dehò, F., additional, De Cobelli, F., additional, Salonia, A., additional, Montorsi, F., additional, Capitanio, U., additional, and Briganti, A., additional

Published
2023
Full Text
View/download PDF

46. Is there an impact of the center performing baseline multiparametric MRI on active surveillance outcomes in prostate cancer patients?

Author

Leni, R., primary, Stabile, A., additional, Gandaglia, G., additional, Mazzone, E., additional, Cucchiara, V., additional, Rosiello, G., additional, Sorce, G., additional, Robesti, D., additional, De Angelis, M., additional, Scuderi, S., additional, Cannoletta, D., additional, Brembilla, G., additional, Esposito, A., additional, De Cobelli, F., additional, Montorsi, F., additional, and Briganti, A., additional

Published
2023
Full Text
View/download PDF

47. Utility of pre- and post-pembrolizumab (Pembro) Vesical Imaging–Reporting and Data System (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): An analysis of the PURE-01 cohort

Author

Necchi, A., primary, Basile, G., additional, Bandini, M., additional, Raggi, D., additional, Marandino, L., additional, Costa De Padua, T., additional, Patanè, D., additional, Crupi, E., additional, Del Prete, A., additional, Colombo, R., additional, Colecchia, M., additional, Luciano, R., additional, Moschini, M., additional, Ross, J., additional, Gibb, E., additional, Briganti, A., additional, Montorsi, F., additional, De Cobelli, F., additional, and Brembilla, G., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results